Long-Term Suppression of HIV Infection: Benefits and Limitations of Current Treatment Options

References 

1. Berger DS, Bellos N, Farthing C, Stryker R, Colson AE, Pierone G, et al. December TMC114/r in 3-class-experienced patients: 24-wk primary safety analysis of the Power 2 study (C202). Washington, DC: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005;Abstract H-1094
2. Boehringer Ingelheim Pharmaceuticals, Inc.. Aptivus prescribing information. Ridgefield, CT: Author; 2006;
3. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, Berry SH, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. New England Journal of Medicine. 2001;344:817–823
4. Bristol-Myers Squibb Company. Sustiva prescribing information. Princeton, NJ: Author; 2005;
5. Department of Health and Human Services. (2006, October). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Retrieved December 11, 2006, from http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=OfT&GuidelineID=7&ClassID=1.
6. Grinsztejn B, Arasteh K, Clotet B, Cunha CA, Goffard JC, Spinosa-Guzman S, et al. July TMC114/r is well tolerated in 3-class-experienced patients: Week 24 primary safety analysis of POWER 1 (TMC114-C213). Rio de Janeiro, Brazil: Third International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005;Abstract WePeLB6.201
7. Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection 2006 Recommendations of the International AIDS Society–USA Panel. Journal of the American Medical Association. 2006;296:827–843
8. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. The Lancet. 2006;368:466–475
9. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685–694
   • MEDLINE
10. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711–718
    • MEDLINE
11. Katlama C, Carvalho MTM, Cooper D, DeBacker K, Lefebvre E, Pedro R, et al. July TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: Week 24 primary efficacy analysis of POWER 1 (TMC114-C213). Rio de Janeiro, Brazil: Third International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005;Abstract WeOaLB0102
12. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. Journal of Infectious Diseases. 2004;189:51–60
13. Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Murtaugh T, et al. October 873140, a novel CCR5 antagonist: antiviral activity and safety during short-term monotherapy in HIV-infected adults. Washington, DC: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004;Abstract H-1137b
14. Ledergerber B, Egger M, Opravil O, Telenti A, Hirschel B, Battegay M. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study (Swiss HIV Cohort Study). The Lancet. 1999;353:863–868
15. Malan N, Krantz E, David N, Kastango K, Frederick D, Matthew M, et al. February Efficacy and safety of atazanavir-based therapy in antiretroviral naïve HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089. Denver, CO: 13th Conference on Retroviruses and Opportunistic Infections; 2006;Abstract 107LB
16. Murphy RL, Sanne I, Cahn P, Phanuphak P, Percival L, Kelleher T, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17:2603–2614
    • MEDLINE
    • CrossRef
17. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine. 1998;338:853–860
18. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. The Lancet. 2003;362:1267–1274
19. Raffi F, Katlama C, Saag M, Wilkinson M, Chung J, Smiley L, et al. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus optimized regimen only (TORO) trials. Clinical Infectious Diseases. 2006;42:870–877
20. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. Journal of Infectious Diseases. 2005;191:825–829
21. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissey JF, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. Journal of Acquired Immune Deficiency Syndromes. 2004;36:1011–1019
22. Tibotec Therapeutics, Division of Ortho Biotech Products, L.P.. Prezista prescribing information. Raritan, NJ: Author; 2006;
23. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN study. The Lancet. 2004;363:1253–1263
24. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New England Journal of Medicine. 2002;346:2039–2046
25. Wilkin T, Haubrich R, Steinhart CR, Becker S, Conant MA, Vangeneugden T, et al. December TMC114/r superior to standard of care in 3-class-experienced patients: 24-wks primary analysis of the POWER 2 study (TMC114-C202). Washington, DC: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005;Abstract 2860